Promising combination treatment gives additional hope to patients with the most aggressive form of skin cancer

New data announced has demonstrated that combinational treatment of cobimetinib with Zelboraf® (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, (1,2) in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone. (3)
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Industry News Oncology advanced melanoma BRAFV600 mutation-positive cobimetinib Latest News vemurafenib Source Type: news